Good day and welcome to the Arcutis Biotherapeutics 2023 fourth quarter and full year financial results conference call. At this time, all participants are in listen-only mode. After the speaker presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising that your hand has been raised. To withdraw your question, please press star one one again. Please be advised that today's conference is being recorded. I would now like to hand the call over to Derek Cole, Arcutis Investor Relations. Please go ahead. Thank you, Andrew. Good morning, everyone, and thank you for joining us today to review 2023 financial results and a business update. Slides for today's call are available on the investor section of the Arcutis website. On the call today, we have Frank Watanabe, President and CEO; Patrick Burnett, Chief Medical Officer; Todd Edwards, Chief Commercial Officer; and John Smither, Chief Financial Officer. I'd remind everyone that we will be making forward-looking statements during this call. These statements are subject to certain risks and uncertainties, and our actual results may differ. We encourage you to review all the company's filings with the Securities and Exchange Commission, including descriptions of our business and risk factors. With that, let me hand the call over to Frank. Thanks, Derek. I'm now on slide five of the deck. We've had a lot of really exciting progress since we last spoke for our Q3 earnings call, and I couldn't be more pleased with the Arcutis team and our execution in the quarter, nor more excited about the foundation these results lay down for progress in 2024. We continue to see growing momentum in the ZORYVE cream launch in psoriasis as healthcare providers and their patients see how it addresses real needs in their treatment of psoriasis. We've now generated over 165,000 prescriptions and over 10,700 unique prescribers to launch to date as our product delivers positive clinical experience for HCPs and their patients. We continue to make significant progress on our gross-to-net each quarter, with improvement in Q4 over Q3 of a similar magnitude as seen Q3 over Q2, taking us to an average in the mid-60s for the fourth quarter. The solid growth in prescriptions, coupled with continued gross-to-net improvements, drove strong revenue growth in Q4, both versus Q3 and year-over-year, with fourth-quarter net revenue of $13.5 million. Coming on top of our progress with ZORYVE cream in psoriasis, we also received approval for ZORYVE foam for seborrheic dermatitis in December and launched in late January. I don't think I've ever seen comparable levels of excitement among patients and dermatologists as what we're hearing about ZORYVE foam. We also continue to execute against our clinical and regulatory milestones with a steady flow of successes this past quarter. Patrick will go into a little more details in a minute, but during the quarter, the FDA accepted our supplemental NDA for atopic dermatitis down to the age of six and assigned a target date of July 7, 2024, potentially expanding our portfolio even further. We also released very exciting interim long-term data from our open-label study in AD that demonstrated efficacy continues to improve with long-term use out to 52 weeks, along with favorable long-term safety and dependable disease control. We've seen robust, consistent, and predictable efficacy across all targeted indications, including psoriasis, seb derm, and atopic dermatitis, in each of their respective pivotal trials. In addition, in October 2023, the U.S. Patent and Trademark Office awarded the company a new formulation patent that covers a means for inhibiting roflumilast crystal growth that is not limited to hexylene glycol. In November 2023, the company was also awarded a new method of treatment patent covering topical roflumilast formulation with an extended half-life. Both patents do not expire until 2037. In October, we completed a secondary offering that raised $102 million, putting us in a strong financial position to continue investing in the ongoing launches in plaque psoriasis and seb derm, as well as the potential atopic dermatitis launch later this year while continuing the development of our pipeline. Moving on to slide 6, a major reason why we're so excited for this year is that we are in the midst of a very significant expansion of the opportunity for topical roflumilast, which we expect will translate into a substantial acceleration of our revenue trajectory. You've seen this before, but from the initial approval for psoriasis, the total addressable market for ZORYVE could grow around tenfold this year alone to over 15 million patients in the United States. We have the right commercial team in place for success, and we have an excellent plan to execute against these opportunities. With that, let me turn it over to Todd to provide some further commentary around the ZORYVE cream launch in psoriasis and update you on how the foam is progressing in seb derm. Thank you, Frank, and I'm very enthusiastic about our growing commercial portfolio, recent progress, and the tremendous opportunity I see ahead. Moving to slide eight, the ZORYVE psoriasis launch is accelerating, and our execution strategies are showing signals that we are able to push the launch trajectory in psoriasis. These efforts also lay a solid foundation for sustained growth in seb derm and potential further growth in new indications upon approval. The NRX and TRX prescription volume is growing every quarter, and ZORYVE has over 165,000 TRXs launched to date. Fourth quarter 2023, TRXs were up 26% compared to Q3 2023 and over 290% compared to the fourth quarter of 2022. We are starting to see a preference for ZORYVE relative to the nonsteroidal competitor, as evidenced by our steady gains in market share, and eight in 10 ZORYVE writers are increasing their utilization of ZORYVE. The new pediatric label expansion down to six years of age incrementally expands our opportunity for growth and further strengthens ZORYVE's safety and tolerability profile. Refills continue to be an important driver of long-term growth. The number of refills in the fourth quarter increased by around 39% versus the third quarter and now constitute more than one in three prescriptions, which is in line with what we want and expect to see given the positive experience patients have with ZORYVE. I am now on slide nine. There are multiple important dermatology conferences in January. After spending time with dermatologists, NPs, and PAs currently using ZORYVE cream, the feedback I receive about the product is exceptional. These prescribers spoke to me about their patients being delighted by the results achieved with ZORYVE. The prescriber feedback is clear that there are some distinct attributes of ZORYVE cream that make it attractive: the ability to be used anywhere, once daily dosing, compelling efficacy data, favorable tolerability profile, safety and appropriateness for any psoriasis patient. These attributes make ZORYVE cream an attractive treatment for patients with different types of needs: the patient who is concerned about steroids, the patient who has been cycling through various topicals, or ones that are exploring different treatments to find that works for them long-term or to manage flares. We know that psoriasis patients have differing needs depending on where they are in their journey and see that ZORYVE cream can really be a solution for most of these patients. I'm now on slide 10. The team has been focused on three pillars of commercial success for sustaining ZORYVE cream growth in psoriasis. Firstly, driving HCP awareness and use. The prescriber base is growing steadily, with now over 10,700 unique prescribers since launch. Our experienced field sales team is focused on high-volume geographies. The field team continues to deliver broad efficacy messaging to move physicians along the adoption curve from initial trial in specific regions of the body to expanded use for patients who have psoriasis plaques across a large body surface area. Secondly, patient engagement and positive use experience. Refill volume has increased to 38% of total volume, and ZORYVE patient awareness continues to improve. And finally, the broad high-quality access in commercial and anticipated Medicare/Medicaid coverage creates the opportunity for more patients to experience ZORYVE. ZORYVE's differentiated pricing and access strategy continues to resonate with payers, with over 132 million commercial lives having access to ZORYVE cream. The Arcutis team successfully secured coverage for ZORYVE cream with all three large PBMs in the U.S. Within 12 months of the launch, and we anticipate further improvements in ZORYVE commercial coverage throughout 2024. PAs and step edits are typical for branded products in dermatology, and for ZORYVE, this process is now well understood by pharmacies and dermatology offices. We are seeing very encouraging trends in percentage of cream prescriptions being covered by insurers, with a clear opportunity to expand on this by working with contracted pharmacy partners. From my experience, I am confident in our ability to continue to improve our gross-to-net. We saw very good improvements in gross-to-net during Q4 and expect that progress to continue in subsequent quarters, with us approaching our target gross-to-net in the 50s for the psoriasis indication by the second half of 2024. One very large incremental opportunity to accelerate prescription growth is the expansion into Medicaid and Medicare, which we expect to begin as early as 2024. Roughly a third of psoriasis patients and nearly half of seb derm and atopic dermatitis patients are on Medicare or Medicaid, so this is a very important opportunity for us. ZORYVE's pricing falls below the CMS specialty threshold tier, unlike other branded topicals, so we are well positioned to access these segments. Now, moving on to slide 11. We are seeing a tremendous early response to the launch of ZORYVE foam, the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades. As you have likely seen in IQVIA data, we have a strong start to the launch with a very positive launch trajectory. The first approved treatment, unconstrained by severity, duration, and location. ZORYVE foam is different than anything else derms or patients have seen for this disease, with treatment success in eight and 10 patients in our pivotal trial, with over half of these patients completely clear in just eight weeks. Significant impact on itch, most bothersome symptom of this disease, with improvements seen as early as 48 hours. Simple, once-daily leave-in application that's much more convenient than any other option. And taken together, we believe ZORYVE foam can be the new standard of care in managing seb derm. I'm now on slide 12. With a product profile offering rapid, dramatic disease clearance and significant reduction in itch, with a simple single treatment, HCPs and patients are very enthusiastic about the availability of ZORYVE foam. 81% of survey prescribers view the ZORYVE foam profile as very compelling or compelling. They also recognize the attributes of applicability to any part of the body, the uniqueness of the vehicle, and critical efficacy needs for this patient type of rapid response to itch and erythema, which then helps to reduce the number of treatments in the regimen and potentially leads to improved compliance. On slide 13, as mentioned previously, we have secured access with the three national PBMs who recognize ZORYVE foam as a line extension under the ZORYVE cream contracts. This has translated into an increased volume of covered prescriptions early in the launch period, with covered prescriptions already near 50% of total volume. We continue to work with the downstream health plans, getting them on board, and this accelerated coverage will translate into a more rapid improvement in gross- to- net compared to what we saw with the cream launch or what is launchable with the new derm products. Finally, all the key EMRs already have ZORYVE foam available for electronic prescribing. Moving to slide 14. Building on the strength of the label and product profile, we are confident that we have the ingredients in place for successful launch of ZORYVE foam in seb derm, with relationships already built with dermatologists, a field team trained on the value proposition and ready to promote and educate, contracted pharmacies in place, familiarity with the copay card and processes that go with the product, and access with PBMs to ensure patients get the drug. I look forward to updating you further on our commercial progress throughout the year. We are also looking forward to upcoming launches and new indications, and so I will hand it over to Patrick to cover that. Thanks, Todd. I'm extremely proud of the team's performance in delivering on the promise of topical roflumilast in the dermatology community and hitting all our timelines with regard to our regulatory milestones. On slide 16, I'm going to cover these according to indication with psoriasis first. Here we have approval down to the age of six after we have expanded the indication, and the opportunity in pediatrics to reach the two to five-year-olds will be the subject of a future FDA review. Next, for seb derm, with our approval in December and the recent launch, physician excitement is palpable, and the feedback at medical congresses has been very positive. The profile here is unprecedented efficacy with a once-a-day foam in a market as big as psoriasis with no innovation in decades and no branded competition. So moving on to atopic dermatitis, as Frank mentioned, the FDA accepted our sNDA for roflumilast cream as a potential treatment for atopic dermatitis for patients down to the age of six, and they assigned a PDUFA action date of July 7th of this year. Finally, we're also expecting to submit another sNDA with the FDA for ZORYVE foam in scalp and body psoriasis in the second half of 2024. On slide 17, I want to highlight some recently released pooled data from our phase III AD studies in INTEGUMENT-1 and INTEGUMENT-2. It's quite notable and highly unusual that over 90% of patients saw improvement in their symptoms in just four weeks, and nearly 70% seeing at least a 50% improvement. Looking at the more demanding EASI 75 hurdle, almost 45% of patients achieved this large improvement at week four. Encouragingly, in the long-term study which we've released but aren't showing here, at the end of 56 weeks, two out of three patients had achieved a 75% improvement. It's really exciting to see where we have a high proportion of patients responding early and then seeing an increased benefit over time with long-term treatment. In that long-term study, we also looked for the first time at our ability to control the disease with a less frequent maintenance regimen, where patients were switched to twice-weekly treatment if they reached complete clearance. We're really happy about the response there. This regimen fits nicely with the current clinical practice, and these data have really resonated with dermatologists. We're excited about the roflumilast cream clinical profile for AD and the significant opportunity in this large and growing market. Dynamics here at AD are favorable towards rapid adoption and share some of the positive tailwinds as seb derm. In pediatric patients especially, here in AD, there's a propensity to adopt nonsteroidals higher than in the psoriasis patient population, and that's largely driven by parents' avoidance of steroids. Moving on to slide 18, I want to highlight the itch response across our portfolio of products. Here we're showing WI-NRS, or Worst Itch Numeric Rating Scale results of our phase III studies. These are pooled results for psoriasis, seb derm, and the AD INTEGUMENT studies, and these are individual study results for STRATUM and ARRECTOR. Itch is a primary symptom for these conditions and a key driver of our quality of life impact. ZORYVE cream and foam at 0.3% and topical roflumilast 0.15% cream for AD provided consistent and rapid improvements in itch across psoriasis, seb derm, and AD respectively, with improvements as early as 24-48 hours as compared with vehicle-treated patients. This includes scalp psoriasis in the ARRECTOR study, which is particularly difficult to control, and only four weeks of treatment in the INTEGUMENT studies. Across indications, we have a significant proportion of patients achieving an itch-free state. With that, I'll pass it over to John. Ladies and gentlemen, please stand by. Please stand by. Ladies and gentlemen, please stand by. Operator, can you hear me? This is Frank. Yes, I can hear you now. Okay. While we're working on John, I'll take over for him for just a minute. So if you're listening still, I'm on slide 20. So we achieved $29.2 million in net product revenue for ZORYVE for the full year 2023, with $13.5 million of that in Q4 reflecting a 67% growth from Q3 to Q4, which comes on top of the approximately 70% sequential growth we saw from Q2- Q3. This was driven by substantial growth gross net, excuse me, percentage improvement down to the mid-60s and the team's success in pulling through covered prescriptions. We also saw healthy prescription growth in the quarter. Looking forward to 2024, we expect continued prescription growth and gross-to-net improvements for ZORYVE cream in psoriasis and continued prescription momentum and GTN improvements for ZORYVE foam, although there will likely be a temporary erosion in psoriasis gross-to-net improvements in Q1 2024 versus Q4 2023 due to the typical deductible resets and patients changing their coverage that always occurs at the beginning of the year. Turning to slide 21, you can see the strong performance in the fourth quarter with net product revenues for the quarter of $13.5 million, up over $10 million from Q4 of 2022. R&D expenses for the fourth quarter were $23.8 million, which is down significantly from Q4 2022 due to continued decrease of development costs on topical roflumilast programs. Recall that our R&D expense includes research, operations, and medical affairs spend. On slide 22, looking at full year, full year total revenues of $60 million, with $29.2 million in net product revenues and $30 million in other revenues related to the upfront payment in connection with the Huadong collaboration and licensing agreement we received in Q3. R&D expenses for full year were $111 million, which is down $70 million approximately due to the one-time $30 million fee associated with the Ducentis acquisition in 2022, the winding down of our major roflumilast phase III studies and lower pre-commercial production. We expect full year 2024 R&D expense to decline meaningfully versus full year 2023 as we continue completing the few remaining phase 3 studies, continue with regulatory filings, reduce our pre-launch production costs, and maintain our medical affairs activity to support the launches. SG&A expenses for the year were $185 million, primarily due to higher commercialization expenses year over year driven by continuing investments in ZORYVE cream and preparing for the ongoing launch of ZORYVE foam and the potential upcoming launch in atopic dermatitis if approved. As we head into 2024, we expect SG&A to increase over 2023, which aligns with the investment behind our seb derm launch and preparations for the atopic dermatitis launch, including our previously announced incremental expansion of sales force. We will continue to focus on appropriate investments to support our commercial activities. Launching drugs properly requires substantial investments in staff and promotional investment, and having multiple launches in a short period of time really magnifies these resource demands. It's important to note that we have made concerted efforts to adjust our operating expenses to reflect our transition from being exclusively a pre-commercial company to a commercial enterprise and ensuring we invest appropriately in current launches and, if approved, ensuring the same for our future launches. We don't want to be in a position of underinvesting and harming the trajectory for the ongoing launches in psoriasis and seb derm or future launches if approved. Earlier in the year, we undertook a reorganization and reprioritization of non-commercial efforts to align with our commercial execution focus in 2024, which will result in an aggregate of approximately $50 million of reduced expenses over the next two years as compared to previous internal forecasts. You can expect us to continue to focus on cash burn as we look for opportunities to maximize our OpEx while making continued progress on maximizing the ZORYVE opportunity across multiple unique indications. A top priority for our team is being good stewards of the investor capital entrusted to us, and we believe we have demonstrated an excellent track record thus far. We have made appropriate levels of investment that established our pipeline, achieved nine positive phase three clinical trials, and now two FDA approvals, with a third potentially coming mid-year while launching two products to date and, if approved, another in the second half of 2024 and a fourth in 2025. On slide 23, our final slide on the balance sheet, we had cash and marketable securities of $272.8 million as of December 31st. As I mentioned on a previous slide, our current capital enables us to continue to invest appropriately in commercial initiatives. We also remain confident about concluding an out-licensing deal in Japan to bring in additional non-dilutive capital, which would further extend runway and largely address the capital requirement covenant with SLR. Additionally, we are actively pursuing a primary care partnership and are seeing early interest from our efforts there. That's it for our comments today. If I step back for a minute, we founded Arcutis with a vision of bringing meaningful innovation to the medical dermatology space, especially the topical space. With our second launch in less than 18 months, I'm proud that our team is making that vision a reality and in the process is helping a growing number of people suffering from dermatologic conditions. As we continue to execute on the psoriasis and seb derm launches and hopefully adding the atopic dermatitis launch later this year, we look forward to helping millions of people, allowing us to create additional shareholder value. We are confident that 2024 will be a transformational year for Arcutis. With that, we will open it up for Q&A. Thank you. As a reminder, to ask a question, please press star one one on your telephone and wait for your name to be announced. To withdraw your question, press star one one again. One moment, please. And our first question comes from. Frank, I think we're back on. Tyler Harris with TD Cowen. Your line is now open. All right. I think that's me. Good morning, guys. Thanks for taking the question. So the seb derm prescriptions for ZORYVE foam have gone vertical very early in the launch and have reached levels that ZORYVE cream and VTAMA took significantly longer to reach. So I understand that having coverage from day one is a huge benefit, and there's not a direct competitor. But what else would you attribute the success to early on? And do you think ZORYVE foam could ultimately end up being significantly larger than the cream? Yeah. I think maybe, Todd, if you could take that and then Patrick, see if you have any additional comments after Todd's come in from a commercial standpoint. Yeah. Thank you, Frank. And yeah, as mentioned, we're very pleased with the uptake of ZORYVE foam. And I mean, with the weekly demand trends, I'd say it's too early to comment on how much of that is coming from a warehouse of patients. But I would say that one big driver of this initial uptake is just that, that it's a ready pool of patients that are out there. And these patients have been waiting for ZORYVE foam. They've been waiting for a more convenient, more effective treatment. And so I think that that's been driving this. But we expect continued strong growth of the product. But I just cautioned that a linear progression based on the rate trend is probably overly optimistic. But I think that there's a long runway for ZORYVE foam, and we're looking forward to continuing to grow this product. Yeah. Patrick, any additional medical thoughts? Yeah, go ahead. Yeah. Yeah. I think just kind of adding the perspective of how this might fit into practice for dermatologists. Seborrheic dermatitis patients can be a challenging patient type in the dermatology practice just because you've had them in your practice for 10, 15 years sometimes. We know that there's a very long runway for patients before they actually get to a diagnosis. And oftentimes, they've tried everything that's out there. And in this space where we haven't really had any innovation for 10, 20 years remember, this is the first new mechanism of action for a prescription topical in over two decades. I think there really is a lot of interest in having a new therapy. That translates into a level of frustration for the dermatologists that was kind of pent up prior to this because when a patient would come back in, they just had nothing to offer them that wasn't a topical antifungal or a topical corticosteroid. So I think that this is simply a component of solving an unmet need where there are patients who are dissatisfied with the treatments and healthcare providers who haven't really had anything new to offer. And we've heard that in anticipation of the approval and launch for the two or three years while we were running our phase III studies, looking for the FDA to approve the drug, that there was a high level of anticipation for this for those reasons. Thank you. One moment, please, for our next question. Our next question comes from the line of Uy Ear with Mizuho. Hey, guys. Yeah. Thanks for taking my question. So just on the launch, the seb derm launch, could you speak of warehousing effect. Are you sort of suggesting primarily that these are kind of patients who have limited options? And I guess, are you seeing what kind of patients are you seeing generally? Do they tend to be more on the severe side or the mild side? And could you sort of just maybe provide some of the demographics a little bit if you have such data? Yeah. So that's my first question. I'll follow up with a second question. Thanks. Yeah. Uy, I think that the point that we're trying to make is, if you think about it, it's been over 20 years since there was a truly new drug for seborrheic dermatitis. And so there is a very large pool of patients, as Patrick or Todd mentioned, excuse me, who have been eagerly awaiting ZORYVE foam's availability. And I think some of the very early demand is probably these patients who have been, as Patrick mentioned, have been cycling for three years and have been just sitting in the office. And now, all of a sudden, the doctor has a new option, and they're going to put them on ZORYVE foam. So we think that there is this pool of ready-made patients that is helping the early launch. But we want to make sure that folks don't think that that pool will exist forever with this constant stream of very large patients. Having said that, our research suggests that dermatologists see about 75 seb derm patients a month. So it's a very large population of patients, which should sustain long-term growth for us. In terms of your question around the demographics, I think it's really too early for us to have any data on that. We'll be looking at adoption and where doctors are using it as we get farther into the launch. And we'll be able to share some of those data in the future. But at this point in the game, we don't have any data on that yet. Okay. And maybe you can help us understand a little bit. So during the earlier call, the launch call, you indicated there were some scripts that were waiting at the pharmacies. Are you still seeing a significant number of scripts that have not been filled or shipped to consumers? Or at this point, these scripts, they come in, and they are, I guess, readily shipped. Just wondering if there's a large delta. And maybe along that line, could you kind of also help us understand, in your ZORYVE Direct program, is there any differences between the cream and the foam in terms of getting it processed? And if there's any yeah, just wanting a little more clarity on that. Thanks. Sure. Yeah. Sure. Todd, can you take those two? Yeah. Absolutely. As mentioned, prior to the commercial launch, there was a number of prescriptions that were sitting at the pharmacy. But those prescriptions have all been filled and distributed to the patient. So we don't see what I'll call a warehouse of prescriptions sitting currently at the pharmacy today. And relative to our ZORYVE Direct program, and I think this is a big strategic advantage for us, is that the program's identical. It's the same program for ZORYVE cream and psoriasis or for ZORYVE foam and seborrheic dermatitis. And that creates a great efficiency for the dermatology offices, given that two unique products for two distinct patient populations, psoriasis and seb derm, but one process in fulfilling that prescription. And so that is a common process across both products. Okay. Thank you. Thank you. One moment, please, for our next question. Our next question comes from the line of Chris Shibutani with Goldman Sachs. Hi. Thanks for taking our question. This is Stephen on for Chris. One on the seb derm launch. Curious if we should expect any inventory or channel stocking effects in the first quarter? And then as far as the commercial team goes, do you believe the team is currently right size for the psoriasis and seb derm opportunities? And if we should anticipate any changes ahead of atopic derm? Thank you. Yeah. John, do you want to maybe take the channel question? And then, Todd, could you address the team? With respect to Q1, no, we're not anticipating any channel buildup with respect to Q1. Yeah. Then the question relative to being right-sized, especially for the potential atopic dermatitis launch. In anticipation of that launch, we will expand our field sales organization. Today, roughly, we have around 100 field sales individuals within that team. And we'll likely expand that by approximately another 50 sales representatives to make certain that we can get the breadth and depth of prescribing across the two products that are approved today and potentially the atopic dermatitis products. So we will be expanding, and that will be initiated shortly. Okay. Thank you very much. Thank you. One moment, please, for our next question. Our next question comes from the line of Seamus Fernandez with Guggenheim Securities. Hi. This is Colleen on for Seamus. Thanks for taking our question, and congrats on the quarter. We're seeing around 6,000 scripts per week for ZORYVE over the past few weeks. As a conservative estimate, if we annualize those 6,000 scripts for 48 weeks and assume a 60% gross-to-net, by our math, that gives us a little under $100 million for ZORYVE sales. Are we thinking about this the right way for a conservative minimum for 2024, which also isn't taking the atopic dermatitis launch into account? Or are there other factors we should be considering for the year? Thanks. Yeah. I think I'll let John answer that one. Thanks, Frank. Specifically, we're not giving revenue guidance. The 6,000 number, I believe you quoted, is both cream and foam. As Todd had mentioned, we're seeing early signs of strong seb derm. We're seeing improvement around psoriasis. We're in the early part of the launch. So I think we're standing back thoughtfully and looking at how that launch is going. We're quite enthusiastic about how the year will turn out, but we're not giving specific guidance on revenue. As it relates to gross-to-net, just as a reminder, we exited 2023 essentially in the mid-60s%. There is a reset that happens in Q1 as a result of folks' deductible reset and as folks also change their medical plans. So you'll see that probably tick up for psoriasis and seb derm. We're confident, as the year progresses, that gross-to-net will continue to improve toward the end of 2024. I believe in our script, we mentioned our target is in the 50s. Great. Thanks. Thank you. One moment, please, for our next question. Our next question comes from the line of Serge Belanger with Needham. Hi. Good morning. Thanks for taking our questions, and congrats on the progress. I guess a question for Todd related to gross-to-net. I think you reiterated your target to be the mid-50s by the end of the year for, I believe it was, ZORYVE cream and psoriasis. Just curious how we should think about the other products, especially ZORYVE foam, and what will happen to overall gross-to-net once the AD indication comes on board and the managed care component also expands. Thanks. Yeah. Yeah. Thank you. Yeah. As mentioned just by John earlier that we're anticipating the second half of the year to achieve the 50s for the gross- to- net. That is for the indication of psoriasis. It's too early to comment on ZORYVE foam for seborrheic dermatitis. I think the one signal that I mentioned earlier was relative to the covered scripts approaching 50% now of the total volume. And then relative to atopic dermatitis, just as a reminder, these are three unique and distinct products, have separate NDCs. So therefore, they'll have separate unique gross- to- nets. But relative to the potential launch in atopic dermatitis, the PBMs, similar to what happened with ZORYVE foam, will treat the AD launch as a line extension, which will be able to support rapid uptake of covered prescriptions at launch for the atopic dermatitis product. Thank you. One moment, please, for our next question. Our next question comes from the line of Vikram Purohit with Morgan Stanley. Hi. Good morning. Thank you for taking our questions. We had two, one on seb derm and one on AD. So for seb derm, could you remind us how many cans of product you expect patients on the foam to work through annually, understanding it's still pretty early in the launch? And are there any interesting observations you're picking up from the initial phase of this launch on which areas of the body patients are using the product in, how much they're using, and whether they're using it either as monotherapy or as a combination agent? And then on AD, we'd just be curious what your latest thinking is on where ZORYVE cream could fit in, if approved, versus other branded topicals that are or may be on the market by the time ZORYVE launches. Thanks. Sure. Yeah. Todd, do you want to maybe take Vikram's questions? Yeah. For the first question relative to the anticipated number of units, so we're anticipating that per patient, on average, per year, a patient would use 1-2 seb derm units. And then relative to it's a little bit early to be able to tell where patients are using this on the body. Are labels very open relative to anywhere on the body or scalp? And then relative to monotherapy or not, once again, it's too early to tell specifically how dermatologists will likely be using this product. Although I will mention that there has been a lot of feedback from dermatologists relative to the convenience of this product being a monotherapy. And I think that lends back to patients really yearning for something that's more convenient and not having to use 6 products on average per week. And so I think that this is one significant differentiator of the product, to be able to use as a monotherapy, highly effective product anywhere on body and scalp. Thank you. One moment, please, for our next question. Our next question comes from the line of Sean Kim with Jones Trading. Yeah. Hi. Congratulations, and thank you for taking my questions. I guess the one question on Medicaid and Medicare expansion opportunity. So just curious, what are some of the remaining key steps to realize that expansion opportunity in the managed care? And my second question is about the patient awareness. You mentioned about approximately 17% among patients aware of your branded product. Just curious to hear whether the demand for your products has been more on the doctors recommending the products to patients or vice versa, patients kind of requesting the products? And then your expectations going forward, whether that awareness will further increase. Thank you. Sure. Todd, sorry, but I think those probably both are to you too. Yeah. No, thank you. And just clarification on the first question. That was relative to the Medicaid expansion opportunity? Right. Medicaid and Medicare, both. Medicaid and Medicare, both. Fantastic. Yeah. Relative to Medicare, we are currently in negotiations with a couple of the Part D Medicare plans. We're anticipating Medicare coverage at some of those Part D plans to be initiated in the second half of 2024. Relative to Medicaid, very similar timeframe. We're also actively talking and working with some of the state Medicaid plans. We anticipate that those plans will come online near the middle of the year to the second half of the year for the Medicaid plans. Relative to patient awareness and also whether it's physician or doctor-driven, I think right now, it's primarily, for the most part, doctor-driven, given just a new product to market. There has not been any new innovation within this space in two decades and the enthusiasm by providers around this product. I think there's a tremendous push by physicians to their patients to take this product. However, I think over time, that paradigm will shift to the patient as we continue to engage more directly with patients, create awareness to patients through a different mode of engagement opportunities. Sean, maybe just to clarify for you and the other ends, neither Medicare nor Medicaid are binary coverage decisions, right? So in Medicare, the majority of patients are covered by these Part D plans that are run by various PBMs or insurance companies. And so we'll get coverage with individual Medicare providers just as we have with commercial. It won't all come at once. We'll get a little bit here, a little bit there, a little bit the other place. And then in the case of Medicaid, that's administered as a state program through block grants from the federal government. And so you have to negotiate with individual states for Medicaid coverage. And so again, that will be kind of a piecemeal coverage process, in fact, even more fragmented since you're dealing with such a large number of states. Okay. That's very helpful. Thank you for the clarification. Thank you. There are no further questions. Thank you for joining Arcutis today. This does conclude the call, and you may now disconnect.